EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Tezepelumab treatment for allergic bronchopulmonary aspergillosis

Hiroaki Ogata iD, Kachi Sha, Yasuaki Kotetsu, Aimi Enokizu-Ogawa, Katsuyuki Katahira, Akiko Ishimatsu, Kazuhito Taguchi, Atsushi Moriwaki, Makoto Yoshida

Respirology Case Reports · 2023-05 · 11 (5)

DOI: 10.1002/rcr2.1147 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Respirology Case Reports, online erschienen am 17.04.2023. Verfasst von Hiroaki Ogata und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine National Hospital Organization Fukuoka National Hospital Fukuoka Japan. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An 82‐year‐old man had been diagnosed with asthma. He experienced repeated exacerbations requiring treatment with a systemic corticosteroid despite being treated with medications including high‐dose fluticasone furoate/umeclidinium/vilanterol, montelukast sodium, and theophylline; treatment with mepolizumab was then initiated. The patient had been free from exacerbations for 15 months; however, he suffered from post‐obstructive pneumonia and atelectasis secondary to mucoid impaction in the right middle lobe of the lung, accompanied by a productive cough, wheezing, dyspnea, and right chest pain. In addition to the development of mucus plugs, the levels of serum IgE specific to Aspergillus spp. became positive; a definite diagnosis of allergic bronchopulmonary aspergillosis (ABPA) was established. The patient underwent treatment with tezepelumab. Over 3 months, the mucus plugs and pulmonary opacities diminished gradually in parallel with the improvement in the control of asthmatic symptoms. Tezepelumab might provide a novel steroid‐sparing strategy for the management of ABPA, although further studies are required.

Schlagwörter

Stichwörter der Autor:innen

allergic bronchopulmonary aspergillosisasthmamepolizumabmucoid impactiontezepelumab

Autor:innen und Institutionen

  • Department of Respiratory Medicine National Hospital Organization Fukuoka National Hospital Fukuoka Japan.

ORCID-Profile: Hiroaki Ogata

Zitieren

APA

Ogata, H., Sha, K., Kotetsu, Y., Enokizu-Ogawa, A., Katahira, K., Ishimatsu, A., Taguchi, K., Moriwaki, A., & Yoshida, M. (2023). Tezepelumab treatment for allergic bronchopulmonary aspergillosis. Respirology Case Reports, 11(5). https://doi.org/10.1002/rcr2.1147

Vancouver

Ogata H, Sha K, Kotetsu Y, Enokizu-Ogawa A, Katahira K, Ishimatsu A, et al. Tezepelumab treatment for allergic bronchopulmonary aspergillosis. Respirology Case Reports. 2023;11(5). doi:10.1002/rcr2.1147

BibTeX
@article{Ogata2023,
  author = {Ogata, Hiroaki and Sha, Kachi and Kotetsu, Yasuaki and Enokizu-Ogawa, Aimi and Katahira, Katsuyuki and Ishimatsu, Akiko and Taguchi, Kazuhito and Moriwaki, Atsushi and Yoshida, Makoto},
  title = {Tezepelumab treatment for allergic bronchopulmonary aspergillosis},
  journal = {Respirology Case Reports},
  year = {2023},
  volume = {11},
  number = {5},
  doi = {10.1002/rcr2.1147}
}
Kostenlos starten →